Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Results – Baseline Demographics and Disease Activity (Study 1)<br />
Patient characteristic<br />
Placebo<br />
n=50<br />
3 mg BID<br />
n=50<br />
6 mg BID<br />
n=50<br />
ABT-494<br />
12 mg BID<br />
n=50<br />
18 mg BID<br />
n=50<br />
24 mg QD<br />
n=49<br />
Age, mean (SD), years 55 (12) 53 (12) 55 (12) 56 (12) 55 (14) 56 (12)<br />
Female, n (%) 38 (76) 40 (80) 34 (68) 41 (82) 42 (84) 42 (86)<br />
RA duration, mean (SD), years 5.9 (5.3) 3.9 (3.8) 7.0 (5.5) 9.3 (8.6) 7.3 (7.9) 8.3 (7.1)<br />
Previous non-MTX DMARDs, n<br />
(%)<br />
7 (14) 6 (12) 12 (24) 11 (22) 5 (10) 12 (24)<br />
HAQ-DI score, mean (SD) 1.4 (0.7) 1.3 (0.7) 1.6 (0.7) 1.5 (0.6) 1.6 (0.6) 1.5 (0.7)<br />
DAS28(CRP), mean (SD) 5.6 (1.1) 5.5 (1.1) 5.8 (1.0) 5.6 (0.9) 5.7 (0.8) 5.7 (1.0)<br />
CDAI score, mean (SD) 40 (14) 38 (13) 43 (14) 39 (12) 40 (13) 41 (13)<br />
hsCRP >ULN*, n (%) 27 (54) 25 (50) 31 (62) 26 (52) 28 (56) 33 (67)<br />
hsCRP, high-sensitivity C-reactive peptide; ULN, upper limit of normal (ULN=5 mg/L).<br />
<strong>Genovese</strong> MC, et al. Arthritis Rheum 2016;68:2857–66.
Change language